50 studies found for:    myeloma and carfilzomib | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Conditions: Relapse Multiple Myeloma;   Refractory Multiple Myeloma
Intervention: Drug: Carfilzomib
2 Recruiting A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Dexamethasone
3 Recruiting Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Intervention: Drug: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
4 Recruiting Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim
5 Recruiting Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Carfilzomib;   Drug: Dexamethasone
6 Recruiting Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: carfilzomib and panobinostat
7 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
8 Recruiting A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
9 Recruiting Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis
10 Recruiting S1304, Testing Two Doses of Carfilzomib With Dexamethasone for Relapsed or Refractory Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib
11 Recruiting Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib and Dexamethasone
12 Recruiting A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
13 Recruiting Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Carfilzomib;   Drug: Panobinostat
14 Recruiting Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib;   Drug: lenalidomide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
15 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Placebo;   Drug: Dexamethasone
16 Recruiting Ph 1b, Carfilzomib, Bendamustine, Dexamethasone in Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Dexamethasone
17 Recruiting Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Cohort 1: Carfilzomib 15 mg/m2;   Drug: Cohort 2: Carfilzomib 20 mg/m2;   Drug: Cohort 3: Carfilzomib 27 mg/m2
18 Recruiting A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
19 Not yet recruiting Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: selinexor;   Drug: carfilzomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: questionnaire administration
20 Not yet recruiting A Single Arm Study of Carfilzomib in Transplant Eligible High Risk Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib, Cyclophosphamide, Dexamethasone

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years